Medication-Assisted Treatment For Opioid Addiction: Debunking The Myths

“You’re just trading one addiction for another.” It’s probably the single most common thing said to someone starting methadone or buprenorphine for opioid use disorder — by a well-meaning relative, sometimes even by another person in recovery. It’s also not what the clinical evidence shows. Medication-assisted treatment (MAT) is one of the most researched interventions in addiction medicine, and the data consistently points the other way: people who use it are significantly less likely to die of an overdose than people who don’t.

The “Trading One Addiction For Another” Myth

The myth persists because, from the outside, MAT looks similar to the problem it’s treating: a person takes a substance every day, sometimes for years. But “physically depends on a substance” and “has an addiction” are not the same clinical category, even though they get used interchangeably in conversation.

Addiction is defined by compulsive use despite harm — a pattern that erodes someone’s ability to work, maintain relationships, or function day to day. A person stabilized on a properly dosed course of methadone or buprenorphine doesn’t get a euphoric high once their dose is regulated, doesn’t need escalating amounts to feel normal, and can drive, hold a job, and parent without impairment. That’s a meaningfully different picture than active opioid use disorder, and it’s closer to how insulin functions for someone with diabetes — a maintenance medication that restores normal function, not a substance being chased for its effects.

How Buprenorphine, Methadone, And Naltrexone Actually Work

These three FDA-approved medications treat opioid use disorder through different mechanisms, and the differences matter for who they’re a fit for:

• Methadone is a full opioid agonist. It activates the same receptors as other opioids, but at a controlled, steady dose it prevents withdrawal and cravings without producing a high. Because of its potency, it’s dispensed through licensed clinics, typically daily in the early stages of treatment.
• Buprenorphine is a partial agonist — it activates those receptors only partially, which creates a “ceiling effect” that limits both the high and the overdose risk even at higher doses. This is part of why it can be prescribed from a regular medical office rather than requiring a specialized clinic.
• Naltrexone is an opioid antagonist. It doesn’t activate the receptors at all — it blocks them, so if someone uses opioids while on it, they won’t feel the effects. It has to be started after a person has fully detoxed, since taking it too early can trigger sudden, severe withdrawal.

All three work by addressing the same underlying problem: opioid use disorder changes how the brain’s opioid receptors function, and cravings and withdrawal are, in large part, a physiological response to that change. Medication stabilizes that system enough for a person to function and engage in the rest of treatment — it isn’t a replacement for treatment on its own.

What The Data Shows On Overdose And Mortality Risk

This is where the “trading one addiction for another” framing runs into trouble. A widely cited Massachusetts study tracked over 17,000 adults who survived a nonfatal opioid overdose and found that, over the following year, those treated with methadone had a 59% reduction in opioid-related overdose deaths, and those treated with buprenorphine had a 38% reduction, compared to people who received no medication at all. A separate, larger study of more than 40,000 people in community-based treatment found buprenorphine or methadone was associated with a 76% drop in overdose risk within the first three months of treatment.

Federal health agencies, including NIDA and SAMHSA, now describe medication for opioid use disorder — paired with naloxone access — as representing the most effective standard of care currently available. And yet the same research keeps finding that it’s underused: in the Massachusetts study, fewer than a third of overdose survivors received any medication for their opioid use disorder in the following year. The gap isn’t in the evidence. It’s in how many people actually get access to it.

Pairing Medication With Behavioral Therapy

Medication addresses the physiological side of opioid use disorder — the cravings, the withdrawal, the receptor changes that make early recovery so difficult to sustain on willpower alone. It doesn’t, by itself, address the thought patterns, triggers, and life circumstances that led to opioid use in the first place, which is the piece behavioral therapies like CBT are built for.

In practice, that means MAT is almost always delivered alongside counseling, not instead of it. Our medication-assisted treatment program pairs medication management with individual and group therapy, so patients are getting both pieces at once rather than one without the other.

Who This Approach Is Suited For

MAT is generally recommended for anyone with a diagnosed opioid use disorder, particularly those who’ve overdosed, relapsed after detox alone, or struggled to stay in recovery without medication support. It’s not a one-size-fits-all timeline, either — some people use it for a defined period while building other recovery skills and eventually taper off under medical supervision; others stay on it long-term, the same way someone might stay on a maintenance medication for any other chronic condition. Both are legitimate, medically supported paths, and the right one depends on the person’s history, their other treatment needs, and how they’re responding.

FAQ

Is MAT just replacing one addiction with another?

No. At a stable, medically supervised dose, these medications don’t produce a euphoric high or require escalating amounts over time, and patients can work, drive, and function normally — which isn’t the case with active opioid use disorder.

How long do people typically stay on MAT?

It varies. Some people taper off after building other recovery supports; others remain on it long-term, similar to a maintenance medication for a chronic condition. There’s no single required timeline.

Is methadone or buprenorphine more effective?

Both are proven effective and reduce overdose risk substantially. The right choice depends on the severity of the opioid use disorder, prior treatment history, and practical factors like access to a licensed clinic versus an office-based prescriber.

Can someone become addicted to methadone or buprenorphine itself?

Physical dependence can occur, which is expected and managed clinically, but this is different from addiction. Buprenorphine’s ceiling effect and methadone’s controlled, supervised dosing are specifically designed to minimize misuse potential.

Does insurance cover medication-assisted treatment?

Coverage varies by plan and provider, so it’s worth confirming directly, but MAT is widely covered as a standard, evidence-based treatment for opioid use disorder.

Can I stop MAT once I feel stable?

Stopping should happen gradually and under medical supervision rather than on your own, since stopping abruptly increases the risk of relapse and overdose. A care team can help determine if and when tapering makes sense.

Conclusion

If you or someone you love is weighing whether MAT is the right fit, that’s a conversation worth having with a clinical team that can look at the full picture — history, other health needs, and what’s realistic day to day. Our opioid addiction program covers what treatment can look like, and you can always reach out to us directly with questions.